Ozempic and Wegovy contain the same active ingredient (semaglutide) but are FDA-approved for different uses
Among incretin hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) play the largest roles
Tirzepatide outperforms dulaglutide for type 2 diabetes control
Indeed, many maintain a majority of their lost weight for several months following treatment
In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]
The people who could benefit most from these medications are often those least able to afford them, perpetuating a cycle in which geography, income, and health outcomes remain tightly intertwined
